Panoramic: Automotive and Mobility 2025
Hogan Lovells advises MindMed in its US$259 million public offering
| 04
November
2025
Philadelphia – Global law firm Hogan Lovells advised Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company developing product candidates to treat brain health disorders, as the company announced the closing of its underwritten public offering of 21,131,250 common shares, without par value, which included the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of US$12.25 per common share.
All of the shares were offered by MindMed. The gross proceeds from this offering were approximately US$259 million, before deducting underwriting discounts and commissions and offering expenses payable by MindMed.
More information about the transaction can be found here.
The Hogan Lovells Capital Markets team was led by partner Steve Abrams (Philadelphia), counsel Val Delp (Philadelphia), senior associate Tyler Glass (Philadelphia), and associates Spencer Leroux (Northern Virginia) and Kayvon Paul (Philadelphia).
Additional support was provided by senior counsel Henry Kahn (M&A, Baltimore), partners Steven Kaufman (M&A, Washington, D.C.), Caitlin Piper (Tax, Pensions & Benefits, Washington, D.C.), and Lynn Mehler (Pharmaceuticals & Biotechnology, Washington, D.C.), and associate Katherine Kramer (Pharmaceuticals & Biotechnology, Washington, D.C.).
The firm has a long-standing relationship with MindMed, guiding the company’s US$175m underwritten offering of common shares and concurrent private placement in March 2024, and its US$75m underwritten public offering in August 2024.
Press contacts
Press contacts
